Here's what we'll cover
Here's what we'll cover
If you've ever winced at the monthly cost of Wegovy or Mounjaro, you're not alone. Now, a Korean pharmaceutical company called Hanmi is preparing to enter the global GLP-1 market with a drug called Eppe, and it's explicitly positioning the medication to compete on price.
Here's what this development actually means for you as a patient, and what you should realistically expect.
What Is Eppe and Who Makes It?
Hanmi Pharmaceutical is one of South Korea's largest drug manufacturers, with a track record of developing and licensing novel compounds to global partners. Eppe is their GLP-1 receptor agonist, a class of drug that works by mimicking a hormone called glucagon-like peptide-1. This hormone helps regulate blood sugar, slows stomach emptying, and reduces appetite.
GLP-1 medications like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have shown strong results for weight loss and metabolic health. Eppe represents Hanmi's bid to offer a comparable therapy, with pricing designed to undercut the current market leaders.
Hanmi has licensed other drugs internationally before, and Eppe is expected to be positioned in markets where cost is the primary barrier to GLP-1 access, which describes most of the world, including the United States.
Where Does Eppe Currently Stand?
As of mid-2025, Eppe is not FDA-approved for use in the United States. Hanmi is moving toward regulatory submissions in South Korea and other markets first. Any path to the U.S. market would require a full FDA review process, which typically takes one to several years after submission.
This means U.S. patients cannot access Eppe through a licensed pharmacy today. What's happening right now is a market positioning story, with Hanmi publicly signaling that it intends to compete with Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) on affordability.
That signal matters, even before the drug reaches pharmacy shelves in America. Here's why.
Why GLP-1 Competition Is Actually Good News for Patients
The current GLP-1 market has a cost problem. Without insurance, Wegovy can cost over $1,300 per month. Mounjaro can run similarly high. Even with manufacturer savings programs, many patients still struggle to afford consistent access to these medications.
Competition changes that dynamic. When multiple manufacturers offer comparable therapies, pricing pressure builds. We've already seen this pattern play out with other drug classes, where the arrival of biosimilars and generic alternatives brought costs down meaningfully.
Eppe's entry signals something broader: the global race to develop GLP-1 therapies is accelerating. Other companies, including Chinese manufacturers and smaller biotech firms, are also in development. The more options that exist in the market, the harder it becomes for any single company to maintain list prices above $1,000 per month.
For patients, this is a long-term positive. In the near term, however, the practical savings opportunities still come from existing programs.
How Eppe's Mechanism Compares to Existing GLP-1 Drugs
GLP-1 medications vary in how they work. Some target only the GLP-1 receptor. Others target multiple receptors at once, which generally produces stronger weight loss results.
| Drug | Active Ingredient | Receptor Targets | Typical Weight Loss (Clinical Trials) | FDA Approved for Weight Loss |
|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 | ~15% body weight | Yes |
| Mounjaro / Zepbound | Tirzepatide | GLP-1 + GIP | ~20-22% body weight | Zepbound: Yes (Mounjaro: diabetes) |
| Ozempic | Semaglutide | GLP-1 | ~10-15% body weight | No (diabetes use only) |
| Eppe (Hanmi) | Efpeglenatide (efinopegdutide) | GLP-1 | Data still emerging | Not yet |
Eppe's active compound, efinopegdutide, is a GLP-1 receptor agonist that has been studied in clinical trials for both type 2 diabetes and obesity. Early data showed meaningful reductions in blood sugar and body weight, though head-to-head comparisons with semaglutide or tirzepatide in large populations are still limited.
Patients should not assume Eppe will be equivalent in efficacy to Wegovy or Mounjaro based on current evidence. More data is needed, and your physician is the right person to evaluate what fits your health profile.
What This Means for Pricing Pressure in the U.S.
Even if Eppe never reaches American pharmacies, its existence contributes to a broader competitive environment that can influence pricing decisions.
Novo Nordisk and Eli Lilly are both aware that global competition is intensifying. Both companies have made announcements about expanded access programs and pricing adjustments in certain markets. That pressure doesn't come from altruism. It comes from the business reality that other manufacturers are entering the space.
For U.S. patients today, the most direct pricing tools remain:
- Manufacturer savings cards. Novo Nordisk and Eli Lilly both offer programs that can reduce out-of-pocket costs significantly for eligible patients.
- Telehealth providers. Some online prescribing platforms offer compounded semaglutide or tirzepatide at lower costs, though these come with important considerations about quality and regulation.
- Insurance negotiation. Prior authorization processes are frustrating, but approval rates improve when documentation of metabolic health conditions is thorough.
You can browse current GLP-1 Coupons to find the latest savings programs available right now.
Questions to Ask Your Doctor If You're Watching This Space
If you're currently taking a GLP-1 medication or considering starting one, Eppe's development is worth knowing about, but it shouldn't change your near-term decisions. Here are practical questions worth raising at your next appointment:
1. Is my current GLP-1 medication working well for me?
If you're getting results with Wegovy or Mounjaro, a future competitor's approval doesn't mean you should stop or switch. Stability and consistency matter in weight loss treatment.
2. Are there savings programs I'm not using?
Many patients don't know about manufacturer-provided savings cards or income-based access programs. Your prescriber or pharmacist can help.
3. Would I be a candidate for any emerging therapies?
If you're just starting your research, it's worth having an honest conversation about which currently-approved options fit your health history, budget, and goals.
4. What's my plan if costs change?
GLP-1 pricing can shift. Having a backup plan, whether that's a different branded drug, a compounded version through a reputable provider, or a structured pause with dietary support, is smart preparation.
The Bigger Picture: A Maturing GLP-1 Market
Eppe is not an isolated development. It's part of a wave. Danish company Novo Nordisk and American company Eli Lilly currently dominate the GLP-1 weight loss market, but that landscape is changing.
Pharmaceutical companies in South Korea, China, Japan, and across Europe are all advancing GLP-1 compounds. Some target only the GLP-1 receptor. Others are exploring triple-receptor agonists, sometimes called "triple G" drugs, that target GLP-1, GIP, and glucagon simultaneously, which may produce even stronger effects.
For patients who have been waiting for this category of medication to become more affordable, the direction of travel is encouraging. The question is timing, and that's harder to predict.
What's already true: the best GLP-1 providers are increasingly competing on service, access, and price. You have more options today than you did two years ago, and that trend is likely to continue regardless of which specific drugs eventually reach the U.S. market.
No waiting list. No insurance needed.
Frequently Asked Questions
What is Eppe and is it available in the United States?
Eppe is a GLP-1 receptor agonist developed by South Korea's Hanmi Pharmaceutical. It is not currently FDA-approved and is not available in U.S. pharmacies. Hanmi is pursuing regulatory approvals in South Korea and other markets first, and any U.S. launch would require a separate FDA review process.
How does Eppe compare to Wegovy and Mounjaro for weight loss?
Eppe targets the GLP-1 receptor, similar to Wegovy's active ingredient semaglutide. Clinical data on Eppe is still emerging, and there are no large head-to-head trials directly comparing it to Wegovy or Mounjaro. Patients should not assume equivalent efficacy based on available information.
Will Eppe lower the price of Wegovy or Mounjaro?
Not directly or immediately. However, increased global competition in the GLP-1 space, which Eppe is part of, does create long-term pricing pressure on market leaders. Historically, competition in drug markets leads to price reductions over time, but this process can take years.
What is the active ingredient in Hanmi's Eppe?
Eppe's active compound is efinopegdutide, sometimes also referred to as efpeglenatide. It is a GLP-1 receptor agonist that has been studied in clinical settings for type 2 diabetes and obesity management.
What GLP-1 drugs are currently FDA-approved for weight loss?
Currently, Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management. Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes, though they are sometimes prescribed off-label for weight loss.
Should I wait for Eppe before starting a GLP-1 medication?
No. If you and your doctor have determined that a GLP-1 medication is appropriate for your health, waiting for a drug that has no U.S. approval timeline is not a sound strategy. Effective, approved options exist now, and early treatment can have meaningful health benefits.
The Bottom Line for GLP-1 Patients
Hanmi's Eppe is a meaningful development in the global obesity treatment landscape. A well-resourced pharmaceutical company explicitly entering the market with price competitiveness as its strategy is genuinely good news for the long-term affordability of GLP-1 medications.
But "long-term" is the operative phrase. If you're navigating weight management decisions right now, whether that means comparing Wegovy vs. Mounjaro, figuring out how to afford your current prescription, or researching which provider to use, Eppe is background context, not an actionable near-term option.
Here's the practical summary:
- If you're already on a GLP-1 medication that's working, stay the course and continue working with your provider.
- If you're considering starting a GLP-1 and cost is your primary barrier, explore existing savings programs and telehealth options available today.
- If you're watching the market for lower-cost options, the competitive landscape is genuinely improving. Compounding access, biosimilar development timelines, and new entrants like Eppe are all part of a trend that favors patients.
Always consult your physician before starting, stopping, or switching any prescription medication. The GLP-1 space moves quickly, and having a provider who stays informed is one of the most valuable assets you can have.
GLP-1.com keeps this information current for you. Browse our provider comparison tool to find the most affordable and reputable prescribers available today, or check our GLP-1 Coupons page for the latest manufacturer savings programs. You shouldn't have to pay more than necessary for medications that work.